Is CAMRF or DIVO a better dividend investment in 2026?

CAMRF currently yields 3.64% with a 5% 5-year dividend growth rate. DIVO yields 6.62% with 5% growth. The better choice depends on your goal: DIVO offers higher current income.

What is the dividend yield difference between CAMRF and DIVO?

CAMRF has a forward dividend yield of 3.64% ($2.00/share annually). DIVO yields 6.62% ($2.91/share annually). The yield gap is 2.98 percentage points.

Home › Compare › CAMRF vs DIVO

CAMRF vs DIVO: Dividend Comparison 2026

CAMRF yields 3.64% · DIVO yields 6.62%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 DIVO wins by $5.7K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CAMRF

● Live price

3.64%

Share price

$55.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$459.40

Full CAMRF calculator →

DIVO

● Live price

6.62%

Share price

$44.00

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.0K

Annual income

$1,008.47

Full DIVO calculator →

Portfolio growth — CAMRF vs DIVO

📍 DIVO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CAMRF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CAMRF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CAMRF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAMRF

Annual income on $10K today (after 15% tax)

$309.09/yr

After 10yr DRIP, annual income (after tax)

$390.49/yr

DIVO

Annual income on $10K today (after 15% tax)

$562.67/yr

After 10yr DRIP, annual income (after tax)

$857.20/yr

At 15% tax rate, DIVO beats the other by $466.71/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAMRF + DIVO for your $10,000?

CAMRF: 50%DIVO: 50%

100% DIVO50/50100% CAMRF

Portfolio after 10yr

$28.1K

Annual income

$733.94/yr

Blended yield

2.61%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAMRF buys

DIVO buys

No recent congressional trades found for CAMRF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCAMRFDIVO

Forward yield	3.64%	6.62% ✓
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$25.3K	$31.0K ✓
Annual income after 10y	$459.40	$1,008.47 ✓
Total dividends collected	$4.1K	$8.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CAMRF vs DIVO ($10,000, DRIP)

Year	CAMRF Portfolio	CAMRF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$11,064	$363.64	$11,362	$661.96	$298.00 → DIVO
2	$12,214	$375.99	$12,860	$702.91	$646.00 → DIVO
3	$13,457	$387.94	$14,504	$743.56	$1.0K → DIVO
4	$14,798	$399.45	$16,303	$783.73	$1.5K → DIVO
5	$16,245	$410.53	$18,268	$823.31	$2.0K → DIVO
6	$17,803	$421.18	$20,408	$862.17	$2.6K → DIVO
7	$19,481	$431.38	$22,737	$900.20	$3.3K → DIVO
8	$21,286	$441.15	$25,266	$937.31	$4.0K → DIVO
9	$23,226	$450.49	$28,008	$973.42	$4.8K → DIVO
10	$25,311	$459.40	$30,977	$1,008.47	$5.7K → DIVO

CAMRF vs DIVO: Complete Analysis 2026

CAMRF — Stock

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Full CAMRF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this CAMRF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAMRF vs SCHD CAMRF vs JEPI CAMRF vs O CAMRF vs KO CAMRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.